Results 41 to 50 of about 151,984 (257)

Occult mucin-producing urothelial-type adenocarcinoma of the prostate with elevated serum levels of carcinoembryonic antigen and carbohydrate antigen 19-9: Report of an autopsy-proven case

Urology Case Reports, 2019
Mucin-producing urothelial-type adenocarcinoma of the prostate (MPUAP) is a rare, aggressive neoplasm thought to originate from the prostatic urethral urothelium.
Keisuke Nonaka, Yoko Matsuda, Mototsune Kakizaki, Shoichiro Takakuma, Tomoyasu Matsubara, Shigeo Murayama, Toshiyuki Ishiwata, Masashi Kameyama, Kazuto Ogura, Sumiko Kobayashi, Tomio Arai   +10 more
doaj   +1 more source

Liquid biopsy‐based diagnostic evaluation of hypermethylated CpG sites for ovarian cancer diagnosis

Molecular Oncology, EarlyView.
This schematic outlines the workflow from biomarker identification to duplex MethyLight assay validation for epithelial ovarian cancer diagnosis using cfDNA‐based liquid biopsy. Initial screening of hypermethylated CpG candidates (cg02957270, cg10061138 cg00480298, COL2A1) was performed in tissue using ARMS‐PCR, COBRA, qPCR and image analysis. Selected
Deepa Bisht, Sameer Gupta, Amrita Chaurasia, Manisha Sachan   +3 more
wiley   +1 more source

Comparison of the pre-treatment testosterone levels in benign prostatic hyperplasia and prostate cancer patients

African Journal of Urology, 2017
Objectives: To compare serum testosterone and prostate specific antigen (PSA) levels of patients diagnosed of prostate cancer to those with benign prostatic hyperplasia (BPH).
D.E. Orakwe, K.H. Tijani, E.A. Jeje, M.A. Ogunjimi, R.W. Ojewola   +4 more
doaj   +1 more source

ZW4864‐mediated inhibition of the β‐catenin/BCL9/BCL9L complex reveals therapeutic potential in bladder cancer

Molecular Oncology, EarlyView.
BCL9 and BCL9L drive bladder cancer progression by enhancing β‐catenin signaling, promoting proliferation, migration, invasion, and organoid growth. Genetic depletion of BCL9(L) suppresses malignant phenotypes, while pharmacological disruption of the β‐catenin/BCL9(L) complex with ZW4864 inhibits canonical Wnt signaling and tumor‐associated cellular ...
Roland Kotolloshi, Mandy Berndt‐Paetz, Eileen Lerner, Gregoire Najjar, Anca Azoitei, Krishna Pal Singh, Shailendra Kumar Gupta, Olaf Wolkenhauer, Cagatay Günes, Otmar Huber, Marc‐Oliver Grimm, Daniel Steinbach   +11 more
wiley   +1 more source

Diagnostic Values of Serum Total Prostate-Specific Antigen for Detection of Breast Masses Nature in 20-75-Year-Old Women with Breast Mass

مجله دانشکده پزشکی اصفهان, 2017
Background: Previous studies had shown that patients with breast cancer have a high level of prostate-specific antigen (PSA). But there was not any study about the role of prostate-specific antigen in detection of breast cancer.
Gholamreza Mohajeri, Mohamadsaleh Jafarpisheh, Hamidreza Kaviani   +2 more
doaj  

CORRELATION OF SERUM ^|^gamma;-SEMINOPROTEIN AND SERUM PROSTATE-SPECIFIC ANTIGEN IN PATIENTS WITH PROSTATE CANCER

The Japanese Journal of Urology, 1989
Enzyme immunoassays (EIAs) using rabbit anti-gamma-seminoprotein (gamma-Sm) antibody and rabbit anti-prostate-specific antigen antibody (PA) for measurements of gamma-Sm and PA were developed in order to determine the correlation between serum gamma-Sm levels and serum PA levels in patients with prostate cancer.
Deguchi, Takashi, Kuriyama, Manabu, Shinoda, Ikuo, Okano, Manabu, Ban, Yoshihito, Kawada, Yukimichi, Matsui, Hiroe, Yamada, Ami, Tada, Kouji, Kobayashi, Katsuhisa, Saito, Isao   +10 more
openaire   +3 more sources

Loss of AMBRA1 activates MAPK and angiogenesis signaling pathways in melanoma cells

FEBS Open Bio, EarlyView.
Loss of AMBRA1 in melanoma cells activates multiple oncogenic pathways associated with tumor progression. Transcriptomic and protein network analyses revealed that AMBRA1 depletion enhances MAPK/ERK signaling, angiogenesis, TGF‐β/EMT signaling, and Wnt/axon guidance pathways.
Milad Ibrahim, Marco Corazzari, Iman Osman, Jane Armstrong, Noel Carter   +4 more
wiley   +1 more source

Prostate-specific antigen in serum of women with breast cancer [PDF]

British Journal of Cancer, 1995
Prostate-specific antigen (PSA) was recently found in 30% of female breast tumours. In this study we have examined if PSA circulates in the blood of breast cancer patients and if serum PSA has any clinical application. We have compared serum PSA levels between women with and without breast cancer, between women with PSA-positive and PSA-negative breast
M, Giai, H, Yu, R, Roagna, R, Ponzone, D, Katsaros, M A, Levesque, E P, Diamandis   +6 more
openaire   +2 more sources

A Fully Human Engineered Bone Niche With Endogenous Osteoclastogenesis Reveals Osteoclast‐Dependent Osteomimicry in Prostate Cancer Cells

Advanced Healthcare Materials, EarlyView.
A human 3D bone niche integrating osteoblasts and osteoclasts enables co‐culture with prostate cancer cell lines and patient‐derived organoids. The engineered niche (i) models aspects of reciprocal phenotypic regulation between osteoblasts and cancer cells, (ii) captures osteoclast‐enhanced osteomimicry in tumor cells, and (iii) establishes a ...
Andrea Mazzoleni, Robin Dolgos, Thomas Menter, Boris Dasen, Arnaud Scherberich, Clémentine Le Magnen, Manuele G. Muraro, Ivan Martin   +7 more
wiley   +1 more source

Extensive metastases in prostatic carcinoma with normal prostate-specific antigen and raised carcinoembryonic antigen – Small cell carcinoma of prostate: A rare entity

Indian Journal of Medical and Paediatric Oncology, 2018
Small cell carcinoma of prostate is a neuroendocrine tumor of prostate seen in 0.5%–2% of men with carcinoma prostate. Prostate-specific antigen (PSA) is a common tumor marker which is often raised in prostatic carcinoma. However, prostatic carcinoma can
Sanjay Mhalasakant Khaladkar, Kunaal Mahesh Jain, Arijit Ghosh, Rajesh Kuber   +3 more
doaj   +1 more source